Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373839 | 0.93 | CTPS1 (0.49) | CTPS1 | |
| SCHEMBL21373873 | 0.91 | CTPS1 (0.50) | CTPS1 | |
| SCHEMBL22758466 | 0.91 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL24849329 | 0.90 | CTPS1 (0.44) | CTPS1 | |
| SCHEMBL22762263 | 0.88 | CTPS1 (0.48) | CTPS1 | |
| SCHEMBL22758464 | 0.87 | CTPS1 (0.49) | CTPS1 | |
| SCHEMBL22762262 | 0.86 | CTPS1 (0.43) | CTPS1 | |
| SCHEMBL22758519 | 0.82 | CTPS1 (0.50) | CTPS1 | |
| SCHEMBL22758529 | 0.81 | CTPS1 (0.37) | CTPS1 | |
| SCHEMBL22758463 | 0.80 | CYP3A4 (0.37) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-07-29 | — | — | US | claimed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114008039-B | Compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | 斯泰普制药股份公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-112839938-B | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| EP-3870574-B1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-4041723-A2 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041715-A1 | SULFONAMIDE INHIBITORS AS CTPS 1 INHIBITORS | Step Pharma S.A.S. (FR) | 2022-08-17 | — | — | EP | disclosed |
| EP-3980411-A1 | N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Step Pharma S.A.S. (FR) | 2022-04-13 | — | — | EP | disclosed |
| CN-114008039-A | N- (5- (6-ethoxypyrazin-2-yl) pyridin-2-yl) -4- (2- (methylsulfonylamino) pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | 斯泰普制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| CN-112839938-A | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2020245664-A1 | N-(5-(6-ETHOXYPYRAZIN-2-YL)PYRIDIN-2-YL)-4-(2-(METHYLSULFONAMIDO)PYRIMIDIN-4-YL) TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | CTPS1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.